文献速递肝病炎症性肠病

粪便微生物移植治疗原发性硬化性胆管炎患者:一项先导性临床试验

Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

这项开放标签先导性研究纳入10例合并炎症性肠病且碱性磷酸酶(ALP)>1.5倍正常上限的原发性硬化性胆管炎(PSC)患者,单次结肠镜途径粪菌移植(FMT)后随访24周。未发生相关不良事件,30%(3/10)患者ALP较基线下降≥50%;所有患者菌群多样性在移植后第1周即升高(P<0.01),移植物操作分类单元丰度与ALP下降相关(P=0.02)。

要点

  • PSC合并炎症性肠病患者单次结肠镜FMT未发生相关不良事件。
  • 30%(3/10)患者第24周时ALP较基线下降≥50%。
  • 所有患者FMT后菌群多样性升高,最早见于第1周(P<0.01)。

核心结论

  • 据作者所知,这是首项证明FMT用于PSC安全的研究。
  • 细菌多样性增加和移植物定植可能与PSC患者ALP改善相关。

研究设计与样本

  • 开放标签先导性研究,纳入合并炎症性肠病且ALP>1.5倍正常上限的PSC患者。
  • 患者接受单次经结肠镜FMT,在基线及FMT后第1、4、8、12、24周进行肝功能、粪便微生物组和代谢组分析。
  • 主要结局为安全性,次要结局为FMT后第24周时ALP较基线下降≥50%。

主要发现

  • 共10例患者接受FMT,其中9例为溃疡性结肠炎、1例为克罗恩结肠炎。
  • 基线平均ALP水平为489 U/L。
  • 未发生相关不良事件。
  • 30%(3/10)患者ALP较基线下降≥50%。
  • 所有患者FMT后菌群多样性增加,最早见于第1周(P<0.01);移植物操作分类单元丰度与ALP下降相关(P=0.02)。

关键数值与推荐

  • 纳入标准:PSC合并炎症性肠病,且ALP>1.5倍正常上限。
  • 主要结局为安全性;次要结局为FMT后第24周ALP较基线下降≥50%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary sclerosing cholangitis (PSC) is a cholestatic liver disease with no effective medical therapies. A perturbation of the gut microbiota has been described in association with PSC, and fecal microbiota transplantation (FMT) has been reported to restore the microbiome in other disease states. Accordingly, we aimed at evaluating the safety, change in liver enzymes, microbiota, and metabolomic profiles in patients with PSC after FMT. METHODS: An open-label pilot study of patients with PSC with concurrent inflammatory bowel disease and alkaline phosphatase (ALP) > 1.5× the upper limit of normal was conducted. The patients underwent a single FMT by colonoscopy. Liver enzyme profiles and stool microbiome and metabolomic analysis were conducted at baseline and weeks 1, 4, 8, 12, and 24 post-FMT. The primary outcome was safety, and the secondary outcome was a decrease in ALP levels ≥50% from baseline by week 24 post-FMT; stool microbiota (by 16S rRNA gene profiling) and metabonomic dynamics were assessed. RESULTS: Ten patients underwent FMT. Nine patients had ulcerative colitis, and 1 had Crohn's colitis. The mean baseline ALP level was 489 U/L. There were no related adverse events. Overall, 30% (3/10) experienced a ≥50% decrease in ALP levels. The diversity increased in all patients post-FMT, as early as week 1 (P < 0.01). Importantly, abundance of engrafter operational taxonomic units in patients post-FMT correlated with decreased ALP levels (P = 0.02). DISCUSSION: To our knowledge, this is the first study to demonstrate that FMT in PSC is safe. In addition, increases in bacterial diversity and engraftment may correlate with an improvement in ALP among patients with PSC.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Allegretti JR, Kassam Z, Carrellas M, et al. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. Am J Gastroenterol. 2019. PMID: 30730351. doi:10.14309/ajg.0000000000000115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。